1 Analytical validation of a multi-protein, serum-based assay for disease activity 2 assessments in multiple sclerosis 3 Ferhan Qureshi, 1* Wayne Hu, 1* Louisa Loh, 1 Hemali Patel, 1 Maria DeGuzman, 1 4 Michael Becich, 1† Fatima Rubio da Costa, 1† Victor Gehman, 1† Fujun Zhang, 1† 5 John Foley,² Tanuja Chitnis³ 6 ¹Octave Bioscience, Inc., Menlo Park, CA, USA 7 8 ²Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT, USA 9 ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA *These authors contributed equally to this work 10 11 [†]Employee of Octave Bioscience, Inc., at the time the study was completed 12 13 Correspondence 14 Ferhan Qureshi 15 1440 Obrien Drive, Suite B 16 Menlo Park, CA 94025, USA 17 Email: fqureshi@octavebio.com Phone: 650-224-3072 18 19 Fax: 650-479-8876 20 21 **Abbreviations:** 22 %CV, percent coefficient of variation; APLP1, amyloid beta precursor-like protein 1; 23 CCL20, C-C motif chemokine ligand 20; CD6, cluster of differentiation 6; CDCP1, 24 CUB domain-containing protein 1; C_{max}, maximum concentration; CNS, central 25 nervous system, CNTN2, contactin 2; COL4A1, collagen type IV alpha-1; conc, 26 concentration; CSF, cerebrospinal fluid; CXCL9, chemokine (C-X-C motif) ligand 9 27 (MIG); CXCL13, chemokine (C-X-C motif) ligand 13; DMT, disease-modifying 28 therapy; DNA, deoxyribonucleic acid; FLRT2, fibronectin leucine-rich repeat 29 transmembrane protein; Gd+, gadolinium positive; GFAP, glial fibrillary acidic protein; 30 GH, growth hormone; HAMA, human anti-mouse antibodies; HCl, hydrochloride; IL-31 12β, interleukin-12 subunit beta; LLOQ, lower limit of quantitation; LOQ, limit of

quantitation; mAb, monoclonal antibody; Max, maximum; Min, minimum; MOG,

32

Qureshi et al Biomarker Analytical Validation Manuscript MedRxiv 33 myelin oligodendrocyte glycoprotein; MRI, magnetic resonance imaging; MS, multiple 34 sclerosis; MSDA, Multiple Sclerosis Disease Activity; Na, sodium; NfL, neurofilament 35 light chain; OPG, osteoprotegerin; OPN, osteopontin; PCR, polymerase chain 36 reaction; PEA, Proximity Extension Assay; PRTG, protogenin; qPCR, quantitative polymerase chain reaction; R², coefficient of determination; RA, rheumatoid arthritis; 37 38 RF, rheumatoid factor; SD, standard deviation; SERPINA9, serpin family A member 39 9: TNFRSF10A, tumor necrosis factor receptor superfamily member 10A (TRAIL-R1); 40 TNFSF13B, tumor necrosis factor superfamily member 13B (BAFF); ULOQ, upper 41 limit of quantitation; VCAN, versican core protein 42 43 **Key words:** 44 Analytical characterization, analytical validation, biomarker, multiple sclerosis, 45 proximity extension assay 46 47 **Total word count:** 3964 (5000 maximum) 48 Analytical Validation of a Serum-Based Assay for Disease Running head: 49 Activity Assessments in Multiple Sclerosis 50 **Previous presentation:** Part of this work, namely analytical validation of the 51 individual biomarkers in the MSDA Test, was previously 52 presented at the ACTRIMS 2021 Forum, Virtual (February 53 25 27, 2021) and analytical validation of the Disease 54 Activity Score and 4 Disease Pathway Scores, was 55 previously presented at the ACTRIMS 2022 Forum, West 56 Palm Beach, Florida (February 24 □ 26, 2022)

Clinical relevance

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Multiple sclerosis (MS) is a chronic, neurodegenerative, immune-mediated disease of the CNS. MS has a complex disease course with variable clinical outcomes. Although many treatments are effective in early stages of the relapsing/remitting form of the disease, early diagnosis and treatment are critical to managing disease activity and slowing disease progression. One of the major areas of focus in MS research is the identification of biomarkers in biological fluids, such as cerebrospinal fluid or blood, to track pathogenesis, disease activity, and disease progression, which can lead to individualized disease management and improved quality of care. Currently, there are no validated clinical tests that leverage multiple blood biomarkers to track disease activity or progression in patients with MS. Herein, we describe the analytical characterization and validation of a multi-protein, serum-based assay panel developed using Olink® PEA methodology. We demonstrate the extensive characterization of this multi-protein, serum-based assay and establish its accuracy, precision, sensitivity, and robustness. This report will be followed by a complementary clinical validation study investigating the correlation between the proteomic assay results and relevant clinical and radiographic endpoints for patients with MS.

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript 75 Abstract Purpose: To characterize and analytically validate the MSDA Test, a multi-protein, 76 serum-based biomarker assay developed using Olink® PEA methodology. 77 78 **Experimental design:** Two lots of the MSDA Test panel were manufactured and 79 subjected to a comprehensive analytical characterization and validation protocol to 80 detect biomarkers present in the serum of patients with MS. Biomarker 81 concentrations were incorporated into a final algorithm used for calculating four 82 Disease Pathway scores (Immunomodulation, Neuroinflammation, Myelin Biology, 83 and Neuroaxonal Integrity) and an overall Disease Activity score. 84 **Results:** Analytical characterization demonstrated that the multi-protein panel 85 satisfied the criteria necessary for a fit-for-purpose validation considering the assay's 86 intended clinical use. This panel met acceptability criteria for 18 biomarkers included 87 in the final algorithm out of 21 biomarkers evaluated. VCAN was omitted based on 88 factors outside of analytical validation; COL4A1 and GH were excluded based on 89 imprecision and diurnal variability, respectively. Performance of the four Disease 90 Pathway and overall Disease Activity scores met the established acceptability 91 criteria. 92 **Conclusions and clinical relevance:** Analytical validation of this multi-protein, 93 serum-based assay is the first step in establishing its potential utility as a quantitative, 94 minimally invasive, and scalable biomarker panel to enhance the standard of care for

95

patients with MS.

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript 96 What is known and what is new in your work? 97 What's known 98 Multiple sclerosis (MS) has a complex disease course with variable clinical 99 outcomes; early diagnosis and treatment are critical to management of MS. 100 One key focus in MS research is the identification of biomarkers in biological 101 fluids, such as cerebrospinal fluid or blood, to track pathogenesis, disease activity, 102 and disease progression, which may lead to individualized disease management 103 and improved quality of care. 104 There currently are no validated clinical tests that leverage multiple blood 105 biomarkers to track disease activity or progression in patients with MS. 106 What's new 107 The MS Disease Activity (MSDA) Test is a multi-protein, serum-based biomarker 108 assay designed to quantitatively measure disease activity using the protein levels 109 of biomarkers present in the serum of patients with MS. 110 In this study, we evaluated 21 biomarkers, 18 of which were selected for inclusion 111 in the MSDA Test, and extensively characterized the MSDA Test (individual 112 biomarkers and algorithmic scores) by establishing the accuracy, precision, 113 sensitivity, and robustness of the assay. 114 This study serves as a critical first step in the validation of this multi-protein,

115

116

serum-based assay, which will be a quantitative, minimally invasive, and scalable

tool to improve MS disease management.

1 INTRODUCTION

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

Multiple sclerosis (MS) is a chronic, neurodegenerative, immune-mediated disease of the CNS, characterized by inflammatory demyelination and neuronal damage.[1,2] MS has a complex disease course with variable symptoms or manifestations that can range from mild and self-limiting to severe.[1] The clinical course, after the first clinical manifestation of the disease, or clinically isolated syndrome, can vary.[3] The damage caused by MS typically leads to relapses, or acute attack of symptoms, followed by progressive disease.[4] Most treatments are effective in early stages of the relapsing/remitting form of the disease; [4,5] however, a delay in treatment can lead to irreversible damage.[6] Studies show that the extent of remyelination in early MS is greater than in chronic MS.[7] Clinical studies are underway to explore treatments targeting remyelination, which may slow or offset disease progression.[8] The McDonald Criteria, designed to improve the accuracy of MS diagnosis, established the use of MRI to show the accrual of lesions over time and space.[9] The revised McDonald Criteria substituted CSF oligoclonal immunoglobulin G bands for the second clinical/MRI finding.[10] Nonetheless, use of any of these assessments do not always accurately predict disease activity, course, progression, recurrence, or response to treatment.[11-13] As such, there is an unmet clinical need for objective and quantitative measures that can accurately diagnose MS, monitor disease activity, and promote individualized disease management.[13,14] One major area of focus in MS is the identification of biomarkers in biological fluids, such as CSF or blood, to track pathogenesis, disease activity, and progression.[14,15] One of the key therapeutic strategies in MS is to reduce relapse, lesions, and brain atrophy at all disease stages.[4] As a result, new biomarkers for early MS diagnosis and disease activity monitoring can lead to prevention of disease

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript progression, potentially reducing the patient's level of disease worsening.[14] The dynamic range of proteins in CSF presents challenges when differentiating small disease-specific changes from inherent inter-individual differences, especially as it relates to methodological variations.[16,17] CSF collection also requires invasive procedures, such as lumbar puncture. On the other hand, blood-based collection of biomarkers allows for safe, quick, and easy collection. [14] With these considerations, detection of biomarkers in blood is a viable and attractive option for the accurate diagnosis and assessment of disease activity and progression in MS. However, there currently are no validated clinical tests that leverage multiple blood biomarkers to track disease activity or progression in patients with MS.[18] Development of multi-protein assays can be challenging. Each protein biomarker requires specific conditions and methodologies for optimal quantification. The optimal multi-protein assay should be designed so that stability and integrity of all biomarker proteins are maintained and optimized to eliminate cross-reactivity.[19] Larger scale, proteomic techniques allow higher throughput of samples and more timely readout. However, maintaining robustness, repeatability, and sensitivity is challenging, yet critical, to the validation of a multi-protein biomarker panel.[20] Analysis of multiple proteins may more accurately represent the various pathways, processes, and cell types involved in complex disease states and has the potential to deliver more personalized medicine for MS.[20-23] Single proteins may not perform well alone as diagnostic or prognostic markers. However, as part of a multi-protein assay, they may contribute to a clinically useful model when combined with other proteins and biomarkers.[21] Therefore, multi-protein assay platforms have been characterized and validated for complex disease states.[19,21,22,24] The MSDA Test is a multi-protein, serum-based biomarker assay designed to quantitatively measure disease activity using the protein levels of biomarkers present

Qureshi et al Biomarker Analytical Validation Manuscript *MedRxiv* in the serum of patients with MS. Our custom multi-protein assay panel was developed using the Olink® PEA (Olink Proteomics, Uppsala, Sweden) methodology described previously (**Figure S1**).[19] Herein, we describe the comprehensive analytical characterization and validation of the MSDA Test to satisfy the criteria necessary for a fit-for-purpose validation considering the assay's intended clinical use.

2 EXPERIMENTAL SECTION

2.1 Assay development

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

Twenty-one biomarkers were selected for inclusion in the custom assay panel based on statistical associations with clinical and radiographic endpoints as demonstrated in feasibility studies for which >1400 proteins were screened using 2 immunoassay platforms (Table S1). These feasibility studies investigated biomarker associations (single-protein and multi-protein) in both cross-sectional and longitudinal samples relative to several radiographic and clinical MS endpoints, including clinically defined relapse versus remission (exacerbation versus quiescence), the presence and count of gadolinium-enhanced lesions on a matched MRI, annualized relapse rate, and Expanded Disability Status Scale. From these studies, the custom panel of 21 proteins was selected with a primary focus on the detection and prediction of disease activity status. The 21 proteins were chosen based on their statistical significance relative to the aforementioned endpoints and with the intent to comprehensively survey the biological pathways, mechanisms, and cell types associated with MS pathophysiology as determined via literature review, protein-protein interaction modeling, gene set enrichment, and spatial expression profiling, [25] Dynamic range of the individual protein assays was considered, as well as the intent to develop a

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript single multi-protein immunoassay panel for which each protein could be measured in an undiluted serum sample. The MSDA Test algorithm consisting of 18 biomarkers included in the panel was finalized in a subsequent clinical validation study for which independent sample sets were analyzed. The final model was trained and validated relative to the presence and count of gadolinium-enhanced lesions. Serum pools (n=4) were included on all runs during assay discovery and development. They were procured in large volumes, aliquoted, stored at −65°C, and run in triplicate. Serum pools were used solely to assess the analytical performance of the assays and served as process controls to determine acceptability of future analytical runs. The SD of repeated measurements was applied to the expected concentrations. Two assay kit lots of the panel were manufactured for which critical reagents were varied to the extent possible. 2.2 Description of the two-layer stacked classifier algorithm for determination of the overall Disease Activity score A two-layer, L2-penalized logistic regression stacked classifier model was developed and clinically validated in a separate study that optimized the model's performance to classify serum samples based on the presence of gadolinium-enhancing lesions (0 lesions or ≥1 lesions) on an MRI administered within 60 days of blood draw.[26] In the first layer of the model, individual protein concentrations in log₁₀ which were demographically corrected for age and sex and LOQ-imputed (referred to as adjusted concentrations) were used as inputs into the four Disease Pathway models (Immunomodulation, Neuroinflammation, Myelin Biology, and Neuroaxonal Integrity).

The second layer of the model used the adjusted protein concentrations and the

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript output (eg, the probability) of the Disease Pathway models as meta features to calculate an overall Disease Activity score (**File S1, Supporting Information**). Thresholds were established, which corresponded to low (1.0 4.0), moderate (4.5 □ 7.0), and high (7.5 □ 10.0) Disease Activity scores. Analytical characterization and validation of the individual biomarkers were factors used to determine inclusion of those biomarkers in the algorithm. 2.3 Incurred sample reanalysis Incurred sample reanalysis was performed to characterize precision and robustness for the individual biomarkers and the Disease Activity and Disease Pathway scores. Forty-eight individual samples from patients with MS were repeatedly analyzed across 10 plates over ≥5 days with varied equipment, reagents, location, and personnel. Acceptability criteria for individual biomarkers was an average %CV ≤20%, and average SD at all established Disease Activity score levels of ≤1.0 units. The 48 samples broadly represented the expected range of biomarker values and Disease Activity scores in the real-world MS population. 2.4 Assay accuracy, precision, and sensitivity Accuracy for each analyte was determined by mixing serum samples at different ratios and evaluating the percent recovery of the observed concentration relative to the expected concentration. Sample mixing enabled the accuracy assessment to be performed using endogenous protein versus a recombinant protein source. Expected concentrations were calculated by applying the targeted ratios of unmixed samples.

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript The ratios of sample mixtures with two samples were 25%:75%, 50%:50%, and 75%:25%. The ratios of sample blends for mixtures with four samples were 25%:25%:25%:25% and 40%:10%:40%:10%. Additionally, accuracy was also evaluated for the Disease Pathway and Disease Activity algorithms by correlating observed scores with expected scores using the same sample mixtures created for the individual analyte assessments. Intra- and inter-assay precision was measured for each analyte. The %CV was determined using serum pools enabling the assessment to be performed using endogenous protein. Serum pools were manufactured to represent patients with shorter and longer MS disease duration, those with inflammatory disease (rheumatoid arthritis), and one healthy control. Acceptability criteria for intra- and inter-assay precision was established as %CV ≤15% and ≤20%, respectively. Sensitivity was defined as the assay's ability to accurately and precisely detect low concentrations of a given substance in biological specimens. To establish the ULOQ and LLOQ, a LOQ panel was manufactured during assay development. For each analyte, four levels were targeted near the anticipated upper limit (ULOQ 1-4) and four levels were targeted near the anticipated lower limit (LLOQ 5-8). The targeted concentrations were based on expected real-world MS patient sample distributions, the shape of the standard curve, and location of asymptotes. The LOQ

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript panel was run in triplicate over two lots (≥5 runs per lot) and fit to the standard curve. Accuracy, defined as 80-120% recovery relative to the expected concentration and precision (inter-assay %CV ≤20%), were used to establish the acceptability criteria and determine the LLOQ and ULOQ of each analyte. Additionally, individual LOQs were assessed and established separately for each kit lot. The most conservative LOQ levels with acceptable accuracy and precision parameters for both lots were used to establish the final LLOQ and ULOQ. Undiluted serum samples were run in the MSDA Test and as a result, no dilution factor was accounted for in the sensitivity analysis. Therefore, the LLOQ and ULOQ define both the analytical measurement range and the reportable range of the assay. Serum samples that recovered either above the ULOQ or below the LLOQ were reported at the established LOQ concentration (referred to as LOQ imputation). MS serum samples were used to establish MS reference ranges for each biomarker. A diverse set of patient samples were used throughout the assay development process and for the analytical validation studies. A total of 1645 samples from nine deeply phenotyped cohorts were analyzed primarily for evaluating associations of biomarkers with MS disease activity and disease progression endpoints. Additional samples from both patients with MS and other disease states were procured for specific analytical characterization experiments. The 1645 samples that were analyzed for the associations of biomarkers with MS endpoints were combined in the

collected both retrospectively and prospectively from nine US and international sites

subsequent analysis to establish MS reference ranges. These samples were

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript and broadly represent the real-world MS population. The mean ± SD age of these patients at the time of the blood draw was 40.85 ± 11.0 years, with a mean ± SD disease duration of 8.39 ± 8.0 years; 72.8% of the patients were female. For race, the top 3 categories were White (81.4%), unknown/not reported (13.5%), and Black/African American (2.7%). The primary endpoint used to train the finalized MSDA Test algorithm was the presence and count of gadolinium-enhancing lesions on an MRI administered within close proximity to the blood draw. For the 1645 patient samples, 1326 had available gadolinium-positive (Gd+) lesion counts and 53.0% of the patient samples had ≥1 Gd+ lesion. The linear interpolation method was used to establish the 95% interval (2.5th and 97.5th percentiles).[27] The percentile relative to these reference ranges are presented with their protein concentrations. 2.5 Assay interference Assay interference was defined as the effect of a substance present in the sample

Assay interference was defined as the effect of a substance present in the sample altering the correct value of the result or the recovery of samples in the assay. Since patients with MS may be treated with a variety of drugs, potential interference of drugs was tested to determine if their presence would affect measurement of the individual protein biomarkers. Concentrations of common prescriptions, over-the-counter drugs, common MS drugs, and DMTs were spiked into serum samples (Table S2). Concentrations of common prescription and over-the-counter drugs were determined by Sun Diagnostics (New Gloucester, ME, USA) using a commercially available test kit. DMTs were targeted at two times C_{max} from pharmacokinetic studies, or the highest possible concentration allowable for spiking with the procured interferent stock. Finally, a universal mAb standard was tested at two concentrations (424 and 7.93 µg/mL) to cover the two times C_{max} of several mAb DMTs. Endogenous substances (hemoglobin, bilirubin, and lipids) and heterophilic antibodies (RF and HAMA) were also measured. For most interferent substances, the

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript acceptability threshold, or median recovery, for the interference assessment was established as 80 120% relative to a corresponding spike control, except for HAMA for which percent recovery of sample mixtures was evaluated (File S2, Supporting Information). 2.6 Diurnal variability Patient serum samples were collected at days 1 □ 5 and day 12 to characterize biomarker level fluctuations. For each of the six time points per patient, the %CV and the percentage difference of the observed protein concentration relative to the average concentration at all time points were calculated. 2.7 Sample stability In an initial experiment, stability studies for four serum samples were performed to determine the effect that storage and processing conditions can have in a clinical setting. Stability was assessed at the following four temperatures: -65°C or below (-80°C) , -10°C or below (-20°C) , $2-8^{\circ}\text{C}$ (4°C), and room temperature (18–25°C) at the following time points: 4 hours (for 4°C and room temperature) and days 1, 3, 7, 14, and 28 (for −20°C, 4°C, and room temperature). The results from −20°C, 4°C, and room temperature were compared with the control storage condition (-80°C). In a follow-up study, the stability of storage of 14 samples was evaluated at 4°C at days 1-3 and 7 compared with a control storage condition (-80°C) to establish the duration of time samples that can be stored at 4°C. Five freeze-thaw cycles.

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

Qureshi et al Biomarker Analytical Validation Manuscript MedRxiv performed at −65°C or below, were also evaluated using four MS serum samples compared with fresh samples. **3 RESULTS AND DISCUSSION** 3.1 Analytical characterization and validation Experiments were performed between July 2020 and July 2021. Fifty-one plates were run (40 and 11 plates using the first and second lots of manufactured kits, respectively). Based on the analytical validation and characterization of individual biomarkers described below, the 18 out of 21 biomarkers that were included in the algorithm were determined to have acceptable analytical performance. GH and COL4A1 were excluded from the algorithm based on the analytical characterization studies described below. VCAN was not incorporated into the final algorithm due to biostatistical factors unrelated to analytical performance. 3.2 Incurred sample reanalysis All individual biomarkers were determined to have a mean %CV <20% and met established acceptability criteria (Figure 1A). The Disease Activity score and the four Disease Pathway scores demonstrated reproducible results throughout the range of scores (Figures 1B 1F). For the Disease Activity score, the average SD across 48 samples was observed to be 0.3 score units, which is less than one interval (0.5) on the reportable scale, and as a result, met acceptability criteria. Additionally, incurred sample reanalysis showed robustness and equivalency of the assay between lots and laboratories, with the exception of COL4A1 (Table S3). 3.3 Assay accuracy, precision, and sensitivity

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript Samples for the accuracy assessment were selected from an internal MS cohort (n=64) to target both high and low concentrations for the individual biomarkers relative to the MS population. Twenty mixed samples from four selected samples were analyzed for each biomarker. Minimum percent recovery for each biomarker ranged from 78% to 89%; the maximum percent recovery for each biomarker ranged from 99% to 124%. The median percent recovery ranged from 91% to 100% (Figure 2A). Additionally, the Disease Pathway and overall Disease Activity scores were calculated for both observed and expected concentrations of the various sample mixtures. The observed calculated scores correlated with the expected scores; R² ≥0.85 was established as the acceptability criteria (Figures 2B 2F). Twelve replicates per serum pool were analyzed on a single plate for the intraassay precision assessment; <51 values per serum pool were analyzed across 51 plates spanning 2 lots of reagent kits. The intra- and inter-assay precision satisfied the criteria for meeting the precision parameter with most analytes passing the

assay precision assessment; ≤51 values per serum pool were analyzed across 51 plates spanning 2 lots of reagent kits. The intra- and inter-assay precision satisfied the criteria for meeting the precision parameter with most analytes passing the established criteria. Of note, COL4A1 was found to have inferior inter- and intra-assay precision that ranged from 7% to 47% and 15% to 59%, respectively. Based on these findings, COL4A1 was removed from consideration for inclusion in the algorithm. MS serum samples (*N*=1645) were analyzed during the assay development and validation process and used to establish the MS reference ranges for each analyte. Sensitivity analysis demonstrated that the LLOQ and ULOQ of each analyte met the sensitivity requirements established for the assay. The maximum

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

Qureshi et al Biomarker Analytical Validation Manuscript MedRxiv percentage of samples requiring imputation at any LOQ was 1.8% (for NfL at LLOQ) (Table 1). 3.3 Assay interference Most biomarker interactions with interferent combinations, such as common MS drugs, DMTs, and mAbs produced a median recovery that ranged from 80% to 120% (Figure 3). A lower percentage recovery was observed for two biomarkers, COL4A1 and CCL20, demonstrating a potential alteration in the presence of the sample for individual drugs. COL4A1 produced a low percent recovery for several drugs that ranged from 71% to 79%, which was likely an artifact of established assay imprecision (Figure 3 and Figure S2). For CCL20, cefoxitin spiked at 660 mg/dL resulted in a median percent recovery of 77% (Figure S2). Additional assay interferents are shown in Figures S2 (common drugs) and S3 (routine endogenous interferents and heterophilic antibodies). 3.4 Diurnal variability Diurnal variation was evaluated in eight patients over six time points (**Figure S4**). Mean and median percent differences for each biomarker and patient were observed to be within ±20%; mean and median %CV was found to be <30% for 19 of the 21 biomarkers (Table 2). Of note, there were some individual samples that were outside of the acceptable range (±30%; data not shown). In addition, mean and median diurnal variability ≥30% was observed for COL4A1, which may have been due to the imprecision of the assay to detect this biomarker. GH was also found to be more variable compared with the other biomarkers, which is not surprising, as GH has

Qureshi et al Biomarker Analytical Validation Manuscript MedRxiv 391 been previously reported to have a high degree of ultradian and diurnal variability [28] 392 For this reason, GH was removed from consideration for inclusion in the algorithm. 393 3.5 Sample stability 394 In the initial stability study, all biomarkers were stable for up to 1 day at room 395 temperature and at 4°C, and for 28 days at −20°C. For those samples stored at room 396 temperature, CXCL13, IL-12\(\beta\), and TNFSF13B decreased beyond -20\(\text{\pi}\) at 3 days. 397 During a follow-up study, all biomarkers were found to meet acceptability criteria 398 when stored at 4°C, and consistent with the initial study as well as the control 399 condition (-80°C) at follow-up (**Table S4**). In a study to examine the stability of 400 samples after freeze-thaw, most biomarkers met acceptability criteria when 401 compared with fresh sample. Of note, GFAP concentrations decreased beyond -20% 402 for freeze-thaw cycles 4 and 5 (**Table S5**). Finally, score level analysis showed that 403 test conditions were within 3 SDs (±1.5 score difference) from the control conditions 404 during the initial study (**Table S6**) and at follow-up (**Table S7**). From these findings, 405 we showed that biomarker levels were found to be most affected above certain 406 thresholds (room temperature for 24 hours, 4°C for 7 days, -20°C for 28 days, and 407 three freeze-thaws). These data can be used to establish allowable sample handling 408 and storage conditions. Beyond these empirical estimations of protein stability, it is

Qureshi et al Biomarker Analytical Validation Manuscript *MedRxiv* also important to note that statistically meaningful associations of biomarkers with multiple MS endpoints were observed using samples that had been stored at -80°C for extended periods of time. This suggests that the target epitopes for the proteins that were selected for inclusion in the custom assay panel and the final algorithm were sufficiently stable to derive clinically meaningful insights.

4 CONCLUSION

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

The accuracy, precision, and reproducibility of a biomarker assay are critical to its utility as a diagnostic and prognostic tool in the management of complex neurodegenerative disorders such as MS. Additionally, such an assay should be insensitive to external factors such as assay interferents and sample collection, processing, and storage. The Clinical and Laboratory Standards Institute and the United States Food and Drug Administration issued guidance on the development and validation of assays for the detection of serum-based biomarkers.[27,29,30] Parameters such as accuracy, precision, recovery, sensitivity and specificity, quality control, and sample stability need to be optimized for the assay to be properly validated.[27,29,30] Results from our analytical validation experiments to characterize the MSDA Test support that the assay is accurate, precise, sensitive, specific, and robust at determining individual biomarker levels and algorithmic scores, regardless of assay interferents, and validated in terms of sample stability. Our findings of high accuracy and precision for the MSDA Test assay align with those of other validation studies of multi-protein assays utilizing the same, [31,32] as well as alternative[21,22] platforms.

with low intra- and inter-assay variability, which has allowed for large-scale, high

PEA demonstrated high sensitivity, specificity, reproducibility, and repeatability

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript throughput screening of up to 92 proteins in 96 samples simultaneously, with low sample consumption and cost.[19] This platform detected novel protein biomarkers and biomarker combinations for many complex disease states, such as cardiovascular disease,[33-37] cancer,[32,38-40] Alzheimer's disease,[41] and inflammatory diseases such as atopic dermatitis and lupus[42,43]; the platform has also proven useful in aging research.[44] For the MSDA Test, we demonstrated that a focused panel of MS biomarkers can be developed and optimized on the PEA platform with absolute quantitation of the proteins to support a fit-for-purpose analytical validation, thereby enabling clinical use of the assay. Thus far, there are no validated clinical tests that leverage multiple blood biomarkers to track disease activity or progression in patients with MS. This is critical for a disease such as MS, which has a complicated clinical course varying from mild, self-limiting to severe.[1] Although MS disease prognosis is primarily based on clinical evidence, such as relapse rate and disability progression, and diagnostic tests (eg, brain MRI or the presence of oligoclonal immunoglobulin G bands in the CSF),[14] neither can consistently and accurately predict disease course, activity, or prognosis.[13] Given the emphasis on early diagnosis and the efficacy of therapies to treat early stages of the relapsing/remitting form of the disease.[4.5] validation of a biomarker panel remains an unmet need in clinical practice, and use of this biomarker tool should provide diagnostic and prognostic value for the treatment of MS. This study demonstrated identification of biomarkers for this complex disease using the PEA platform. With further clinical validation, this assay can potentially be used to track disease activity and progression of MS, allowing a more personalized approach to MS treatment. A limitation of using a multi-protein assay is that the conditions established for

one biomarker are not always uniform across the full panel of biomarkers. Our

461

462

463

464

465

466

467

468

469

470

471

472

473

474

their physicians.

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript findings show that the MSDA Test was optimized for assessment of 18 out of the 21 included biomarkers and the analytical validation paradigm that we described demonstrates a high level of accuracy, sensitivity, and precision with minimal crossreactivity and interference by substances commonly seen in patients with MS. This study serves as a critical first step in the validation of a multi-protein, serum-based assay. The next step in the validation of the MSDA Test is clinical validation, which will support and confirm the association between the serum-based MSDA Test and clinical and radiographic MS endpoints. Upon completion of clinical validation of the assay, the final Disease Activity and Disease Pathway algorithms will use the ensemble of validated proteins to expand the use of the assay by evaluating biomarker correlations with endpoints associated with additional MS disease assessments, selection of therapy, and differential diagnosis of patients with MS. Upon successful clinical validation, this MSDA Test will be a quantitative, minimally invasive, and scalable tool to improve disease management for patients with MS and

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript 475 **ACKNOWLEDGMENTS** 476 The authors wish to thank the following team members from Olink Proteomics 477 (Uppsala, Sweden) who were involved in the development of the Multiple Sclerosis 478 Disease Activity Test assay: Erika Assarsson, Sandra Ohlsson, Martin Lundberg, 479 Jessica Bergman, and Niklas Nordberg. All authors contributed to and approved the 480 manuscript for submission. Writing and editorial assistance were provided by Jennifer 481 L. Venzie, PhD, and Bu Reinen, PhD, CMPP, of The Lockwood Group (Stamford, 482 CT, USA), and were funded by Octave Bioscience, Inc. 483 484 **CONFLICT OF INTEREST STATEMENT** 485 F. Qureshi, W. Hu, L. Loh, H. Patel and M. DeGuzman are employees of Octave 486 Bioscience, Inc. M. Becich, F. Rubio da Costa, V. Gehman, and F. Zhang were 487 employees of Octave Bioscience, Inc. at the time the study was completed. J. Foley 488 has received research support from Biogen, Novartis, Adamas, Octave Bioscience, 489 Inc., Genentech, and Mallinckrodt, received speakers' honoraria and acted as a 490 consultant for EMD Serono, Genzyme, Novartis, Biogen, and Genentech, and has 491 equity interest in Octave Bioscience Inc., and is the founder of InterPro Biosciences. 492 T. Chitnis has received compensation for consulting from Biogen, Novartis 493 Pharmaceuticals, Roche Genentech, and Sanofi Genzyme, and received research 494 support from the National Institutes of Health, National MS Society, US Department 495 of Defense, EMD Serono, I-Mab Biopharma, Mallinckrodt ARD, Novartis 496 Pharmaceuticals, Octave Bioscience, Inc., Roche Genentech, and Tiziana Life

497

Sciences.

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript 498 **FUNDING** 499 The study was funded by Octave Bioscience, Inc. and in part by the U.S. Department of Defense (W81XWH2110633 to T Chitnis). 500 501 502 DATA AVAILABILITY STATEMENT 503 Access to data can be provided after a research proposal is submitted to the 504 corresponding author and a data sharing agreement is in place.

505 **REFERENCES**

506

- 507 [1] Compston, A., Coles, A. (2008). Multiple sclerosis. *Lancet*, 372, 1502-1517.
- Weiner, H. L. (2004). Multiple sclerosis is an inflammatory T-cell–mediated autoimmune disease. *Arch Neurol*, *61*, 1613-1615.
- 510 [3] Miller, D. H., Chard, D. T., Ciccarelli, O. (2012). Clinically isolated syndromes. 511 Lancet Neurol, 11, 157-169.
- 512 [4] Giovannoni, G., Butzkueven, H., Dhib-jalbut, S., Hobart, J., Kobelt, G., Pepper, G., . . . Vollmer, T. (2016). Brain health: time matters in multiple sclerosis. *Mult Scler Relat Disord*, *9*, S5-S48.
- 515 [5] Macaron, G., Ontaneda, D. (2019). Diagnosis and management of progressive multiple sclerosis. *Biomedicines*, 7, 56.
- 517 [6] Miller, J. R. (2004). The importance of early diagnosis of multiple sclerosis. *J Manag Care Pharm*, *10*, S4-S11.
- 519 [7] Goldschmidt, T., Antel, J., König, F. B., Brück, W., Kuhlmann, T. (2009).
 520 Remyelination capacity of the MS brain decreases with disease chronicity.
 521 *Neurology*, 72, 1914-1921.
- 522 [8] Cunniffe, N., Coles, A. (2021). Promoting remyelination in multiple sclerosis. *J Neurol*, *268*, 30-44.
- 524 [9] McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H.-P., Lublin, F. D., . . . Wolinsky, J. S. (2001). Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. *Ann Neurol*, *50*, 121-127.
- 528 [10] Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., . . . Cohen, J. A. (2018). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol*, *17*, 162-173.
- 531 [11] Tintoré, M., Rovira, A., Río, J., Nos, C., Grivé, E., Téllez, N., . . . Montalban, X. (2006). Baseline MRI predicts future attacks and disability in clinically isolated syndromes. *Neurology*, *67*, 968-972.
- 534 [12] Teixeira, M., Seabra, M., Carvalho, L., Sequeira, L., Abreu, P., Mendonça, T., . 535 . . . Guimarães, J. (2020). Clinically isolated syndrome, oligoclonal bands and multiple sclerosis. *Clin Exp Neuroimmunol*, *11*, 33-39.
- 537 [13] Jafari, A., Babajani, A., Rezaei-Tavirani, M. (2021). Multiple sclerosis 538 biomarker discoveries by proteomics and metabolomics approaches. *Biomark* 539 *Insights*, *16*, 11772719211013352.
- 540 [14] Ziemssen, T., Akgün, K., Brück, W. (2019). Molecular biomarkers in multiple sclerosis. *J Neuroinflammation*, *16*, 272.
- 542 [15] Gul, M., Jafari, A. A., Shah, M., Mirmoeeni, S., Haider, S. U., Moinuddin, S., 543 Chaudhry, A. (2020). Molecular biomarkers in multiple sclerosis and its related 544 disorders: a critical review. *Int J Mol Sci*, *21*, 6020.
- 545 [16] Hühmer, A. F., Biringer, R. G., Amato, H., Fonteh, A. N., Harrington, M. G. (2006). Protein analysis in human cerebrospinal fluid: physiological aspects, current progress and future challenges. *Dis Markers*, *22*, 3-26.
- 548 [17] Zhang, J. (2007). Proteomics of human cerebrospinal fluid the good, the bad, and the ugly. *Proteomics Clin Appl, 1,* 805-819.
- 550 [18] Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., . . . Polman, C. H. (2014). Defining the clinical course of multiple sclerosis: the 2013 revisions. *Neurology*, 83, 278-286.
- 553 [19] Assarsson, E., Lundberg, M., Holmquist, G., Björkesten, J., Bucht Thorsen, S., 554 Ekman, D., . . . Fredriksson, S. (2014). Homogenous 96-plex PEA

- 555 immunoassay exhibiting high sensitivity, specificity, and excellent scalability.
 556 *PLoS One*, *9*, e95192.
- 557 [20] Schubert, O. T., Röst, H. L., Collins, B. C., Rosenberger, G., Aebersold, R. (2017). Quantitative proteomics: challenges and opportunities in basic and applied research. *Nat Protoc*, *12*, 1289-1294.
- 560 [21] Dillon, R., Croner, L. J., Bucci, J., Kairs, S. N., You, J., Beasley, S., . . . Wilcox, B. (2018). Analytical validation of a novel multiplex test for detection of advanced adenoma and colorectal cancer in symptomatic patients. *J Pharm Biomed Anal*, 154, 85-94.
- Eastman, P. S., Manning, W. C., Qureshi, F., Haney, D., Cavet, G., Alexander,
 C., Hesterberg, L. K. (2012). Characterization of a multiplex, 12-biomarker test
 for rheumatoid arthritis. *J Pharm Biomed Anal*, 70, 415-424.
- 567 [23] Chitnis, T., Prat, A. (2020). A roadmap to precision medicine for multiple sclerosis. *Multiple Sclerosis Journal*, *26*, 522-532.
- 569 [24] Bhawal, R., Oberg, A. L., Zhang, S., Kohli, M. (2020). Challenges and opportunities in clinical applications of blood-based proteomics in cancer. *Cancers (Basel)*, *12*, 2428.
- 572 [25] Chitnis, T., Becich, M., Bove, R., Cree, B. A. C., Gehman, V., Gomez, R., Baranzini, S. E. Development of a custom multivariate proteomic serum based assay for association with radiographic and clinical endpoints in MS.

 575 Presented at: Americas Committee for Treatment and Research in Multiple Sclerosis and European Committee for Treatment and Research in Multiple Sclerosis; September 11-13, 2020; Virtual.
- 578 [26] Chitnis, T., Foley, J., Ionete, C., El Ayoubi, N., Saxena, S., Gaitan-Walsh, P., . . . Khoury, S. J. Clinical validation study results of a multivariate proteomic serum based assay for disease activity assessments in multiple sclerosis.

 581 Presented at: 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 13-15, 2021; Virtual.
- 583 [27] Clinical and Laboratory Standards Institute. (2018). EP283CE. Defining, 584 establishing, and verifying reference intervals in the clinical laboratory. 3rd edition.
- Hancox, T. P. M., Skene, D. J., Dallmann, R., Dunn, W. B. (2021). Tick-tock consider the clock: the influence of circadian and external cycles on time of day variation in the human metabolome—a review. *Metabolites*, *11*, 328.
- 589 [29] United States Food and Drug Administration. Bioanalytical method validation: 590 guidance for industry. Accessed September 13, 2021. 591 https://www.fda.gov/media/70858/download
- 592 [30] Clinical and Laboratory Standards Institute. (2016). EP07. Interference testing in clinical chemistry. 3rd edition.
- 594 [31] Xu, Y. W., Peng, Y. H., Chen, B., Wu, Z. Y., Wu, J. Y., Shen, J. H., . . . Xu, L. Y. (2014). Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. *Am J Gastroenterol*, *109*, 36-45.
- 597 [32] Yang, X., Suo, C., Zhang, T., Yin, X., Man, J., Yuan, Z., . . . Ye, W. (2021).
 598 Targeted proteomics-derived biomarker profile develops a multi-protein
 599 classifier in liquid biopsies for early detection of esophageal squamous cell
 600 carcinoma from a population-based case-control study. *Biomark Res*, *9*, 12.
- [33] Hijazi, Z., Wallentin, L., Lindbäck, J., Alexander, J. H., Connolly, S. J.,
 Eikelboom, J. W., . . . Siegbahn, A. (2020). Screening of multiple biomarkers
 associated with ischemic stroke in atrial fibrillation. *J Am Heart Assoc*, 9,
 e018984.


- Sanders-van Wijk, S., Tromp, J., Beussink-Nelson, L., Hage, C., Svedlund, S., Saraste, A., . . . Shah, S. J. (2020). Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study. *Circulation*, *142*, 2029-2044.
- [35] Pol, T., Hijazi, Z., Lindbäck, J., Oldgren, J., Alexander, J. H., Connolly, S. J., . .
 Wallentin, L. (2021). Using multimarker screening to identify biomarkers
 associated with cardiovascular death in patients with atrial fibrillation.
 Cardiovasc Res, cvab262.
- [36] Feldreich, T., Nowak, C., Fall, T., Carlsson, A. C., Carrero, J. J., Ripsweden,
 J., . . . Ärnlöv, J. (2019). Circulating proteins as predictors of cardiovascular
 mortality in end-stage renal disease. *J Nephrol*, *32*, 111-119.
- 616 [37] Nowak, C., Carlsson, A. C., Östgren, C. J., Nyström, F. H., Alam, M.,
 617 Feldreich, T., . . . Ärnlöv, J. (2018). Multiplex proteomics for prediction of major
 618 cardiovascular events in type 2 diabetes. *Diabetologia*, *61*, 1748-1757.
- 619 [38] Leandersson, P., Åkesson, A., Hedenfalk, I., Malander, S., Borgfeldt, C. (2020). A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients. *PLoS One*, *15*, e0240418.
- [39] Enroth, S., Berggrund, M., Lycke, M., Broberg, J., Lundberg, M., Assarsson,
 E., . . . Gyllensten, U. (2019). High throughput proteomics identifies a high accuracy 11 plasma protein biomarker signature for ovarian cancer. *Commun Biol*, 2, 221.
- 626 [40] Berggrund, M., Enroth, S., Lundberg, M., Assarsson, E., Stålberg, K.,
 627 Lindquist, D., . . . Gyllensten, U. (2019). Identification of candidate plasma
 628 protein biomarkers for cervical cancer using the multiplex proximity extension
 629 assay. *Mol Cell Proteomics*, 18, 735-743.
- [41] Whelan, C. D., Mattsson, N., Nagle, M. W., Vijayaraghavan, S., Hyde, C.,
 Janelidze, S., . . . Hansson, O. (2019). Multiplex proteomics identifies novel
 CSF and plasma biomarkers of early Alzheimer's disease. *Acta Neuropathol Commun*, 7, 169.
- 634 [42] Petrackova, A., Smrzova, A., Gajdos, P., Schubertova, M., Schneiderova, P., Kromer, P., . . . Kriegova, E. (2017). Serum protein pattern associated with organ damage and lupus nephritis in systemic lupus erythematosus revealed by PEA immunoassay. *Clin Proteomics*, *14*, 32.
- 638 [43] Brunner, P. M., He, H., Pavel, A. B., Czarnowicki, T., Lefferdink, R., Erickson, T., . . . Paller, A. S. (2019). The blood proteomic signature of early-onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long-standing disease. *J Am Acad Dermatol*, *81*, 510-519.
- [44] Moaddel, R., Ubaida-Mohien, C., Tanaka, T., Lyashkov, A., Basisty, N.,
 Schilling, B., . . . Ferrucci, L. (2021). Proteomics in aging research: a roadmap to clinical, translational research. *Aging Cell*, *20*, e13325.

Qureshi et al MedRxiv Biomarker Analytical Validation Manuscript 646 FIGURE LEGENDS 647 648 FIGURE 1. Incurred sample reanalysis results for (A) Individual biomarkers and (B) 649 Overall Disease Activity score, (C) Immunomodulation, (D) Neuroinflammation, (E) 650 Myelin Biology, and (F) Neuroaxonal Integrity pathway scores in the MSDA Test. 651 652 FIGURE 2. Accuracy of the MSDA Test to detect (A) Individual biomarkers and (B) 653 Overall Disease Activity score, (C) Immunomodulation, (D) Neuroinflammation, (E) 654 Myelin Biology, and (F) Neuroaxonal Integrity pathway scores. 655 FIGURE 3. Assay interference for common MS drugs, DMTs, and the high 656 657 concentration of universal mAb surrogates in the MSDA Test.

Biomarker Analytical Validation Manuscript

MedRxiv


FIGURE 1



Biomarker Analytical Validation Manuscript

MedRxiv


FIGURE 2



Biomarker Analytical Validation Manuscript

MedRxiv

FIGURE 3



BLE 1	Intra-	and i	nter-ass	ay pred	cision, s	sensitivity	, and	referer	nce rang	es for	biomar	kers in t	he MSD/	A Test				
	Precision									Sensitivity and reference ranges								
Analytes	Shorter MS duration pool ^a			Longer MS duration pool ^b			RA pool			Healthy control pool								
	Intra %CV	Inter %CV	Conc (pg/mL)	Intra %CV	Inter %CV	Conc (pg/mL)	Intra %CV	Inter %CV	Conc (pg/mL)	Intra %CV	Inter %CV	Conc (pg/mL)	LLOQ (pg/mL)	ULOQ (pg/mL)	Low MS range (pg/mL) ^c	High MS range (pg/mL) ^d	Samples imputed at LLOQ, % (<i>N</i> =1645)	Samples imputed a ULOQ, % (<i>N</i> =1645
APLP1	9	9	10,296	9	8	11,560	4	8	11,868	7	9	11,868	2323.78	142,798.49	5500	22,000	0	U
CCL20	6	9	6.9	8	7	9.2	5	9	13.7	7	9	11.8	0.92	383.49	2.1	52	0	1 (<0.1)
CD6	6	8	89	8	8	108	5	7	137	8	9	112	4.62	3318.60	46	250	0	0 1 (<0.1)
CDCP1	8	9	78	8	9	125	4	9	208	7	10	72	24.22	6795.04	28	230	23 (1.4)	
CNTN2	6	7	1120	7	7	1643	4	6	1554	8	8	1256	44.46	12,373.51	650	3300	0	0
COL4A1	7	15	1104	19	20	1334	8	59	1601	47	27	1387	30.65	4573.38	520	3600	0	23 (1.4)
CXCL13	6	8	52.8	8	7	42.9	7	8	65.3	7	9	46.8	1.91	1112.70	22	190	0	0
CXCL9	6	11	31.0	8	10	62.6	5	11	112.3	7	11	27.5	1.89	1832.22	17	250	0	0
FLRT2	7	8	103	9	9	110	5	8	139	8	9	116	35.67	10,107.17	63	180	1 (<0.1)	0
GFAP GH	7	18	70 823	10	16 7	126 595	8 5	15 8	148 1010	9	18	77 366	12.46 9.63	19,582.88 18,413.83	24 17	220 9500	16 (1.0)	0 (0.5)
IL-12β	7	9	109	9	7	122	6	8	1118	8	9	71	0.56	3044.33	28	280	7 (0.4)	9 (0.5)
MOG	4	6	21.9	7	6	22.8	5	7	26.0	6	8	17.8	1.75	577.42	12	47	0	0
NfL	10	11	7.6	13	9	15.6	8	8	20.6	11	12	6.5	3.31	599.18	3.5	42	29 (1.8)	0
OPG	6	11	699	9	11	806	6	10	1022	7	12	602	14.58	62,385.21	410	1400	0	0
OPN	6	10	15,733	7	10	15,415	6	12	17,470	7	13	10,450	572.50	157,267.29	9500	39,000	0	0
PRTG	7	6	94	8	7	107	5	6	108	7	7	103	3.90	5920.73	71	180	2 (0.1)	9 (0.5) 0 0 0 0 0 0
ERPINA9	11	8	45.1	11	8	37.9	5	7	60.0	6	14	50.0	5.12	9286.67	12	160	1 (<0.1)	0
RSF10A	9	9	5.1	9	9	5.5	5	8	7.6	9	9	4.9	0.48	1027.28	2.8	9.7	0	0
VFSF13B	7	10	4075	11	11	4019	5	11	4204	7	13	3003	660.29	130,682.08	2300	10,000	0	0
VCAN	7	8	316	7	7	337	4	7	448	5	8	310	8.54	14,673.95	230	600	0	0

^aAverage age of patients with shorter MS duration was 36 (range, 27 □ 43) years.

^bAverage age of patients with longer MS duration was 52 (range, 45□62) years.

^cLow MS range was defined as the 2.5th percentile.

^dHigh MS range was defined as the 97.5th percentile.

Qureshi et al Biom

Biomarker Analytical Validation Manuscript

MedRxiv

TABLE 2 Diurnal variability of eight samples in the MSDA Test across six time

points (days 1, 2, 3, 4, 5, and 12)

ANALYTE	MEAN %CV	MEDIAN %CV
APLP1	14	15
CCL20	25	21
CD6	10	7
CDCP1	12	12
CNTN2	11	10
COL4A1	44	39
CXCL13	18	11
CXCL9	13	11
FLRT2	10	8
GFAP	13	12
GH	78	79
IL-12B	10	9
MOG	12	11
NFL	17	17
OPG	11	10
OPN	10	8
PRTG	8	6
SERPINA9	12	12
TNFRSF10A	10	12
TNFSF13B	11	8
VCAN	10	7

33

Green shading: %CV ≤30%. Red shading: %CV > 30%.

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

Analytical Validation of a multi-protein, proteomic serum-based assay for disease activity assessments in multiple sclerosis

Ferhan Qureshi,* Wayne Hu,* Louisa Loh, Hemali Patel, Maria DeGuzman,
Michael Becich, Fatima Rubio da Costa, Victor Gehman, Fujun Zhang, John Foley,
Tanuja Chitnis

Supporting Information

^{*}These authors contributed equally to this work

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl


FILE S1. MSDA Test algorithm formula

Key to the MSDA Test was the architecture of a stacked classifier (in the mlxtend [1] framework) where each node (blue boxes in the Figure) in both layers are L2regularized logistic regression models from Scikit Learn.[2] The input layer read in demographically corrected for age and sex, log₁₀, LOQ-imputed concentrations of proteins associated with four physiological pathways from each sample and generated probabilities that the sample in question was positive for the presence of Gd+lesions. The meta-classifier (output) layer of the model ingested the probabilities from each pathway model along with all of the protein concentrations that fed the first layer and generated an overall probability that the sample in question was Gd+ lesion-positive. This probability was then mapped into a Disease Activity score by being shifted, scaled, rounded, and clipped to the nearest half point over a range from 1 to 10 (Eq. 1). A similar process converted the pathway probabilities into pathway scores after the pathway probabilities were adjusted so that for each sample, the mean over the adjusted pathway probabilities was equal to the Disease Activity probability for each sample (Eq. 2). The datasets used to develop and evaluate the demographic correction, four Disease Pathway models, and Disease Activity model, as well as the performance of these models, have been described previously.[2]

The process for calculating the Disease Activity score is shown in the **Figure**.

Proteomics Clin Appl

FIGURE. Schematic representation of the Disease Activity score calculation from protein concentrations (green) to both layers of the stacked classifier (blue), the output Disease Activity probability (red), and the final Disease Activity and Disease Pathway score (black).



The overall Disease Activity score had the mathematical form:

$$S_{DA} = \operatorname{Clip}_{0}^{9} \left(\frac{1}{2} \operatorname{Round} \left(18 \times \frac{P_{DA} - P_{DA}^{loow}}{P_{DA}^{High} - P_{DA}^{Low}} \right) \right) + 1 \tag{1}$$

The "Clip" function limited the output of its argument to between 0 and 9. The "Round" function rounded to the nearest whole number. P_{DA} was the Disease Activity probability output from the final stage of the stacked classifier model. P^{High}_{DA} and

Qureshi et al Biomarker Analytical Validation Manuscript $Proteomics Clin Appl P^{Low}_{DA}$ were probability clip values chosen for the overall Disease Activity (and each pathway) to maximize the range of the score over the entire training data set. Their values are tabulated below.

Similar to the Disease Activity score, each pathway score was computed from the pathway probabilities with the additional step of recentering the ensemble of pathway probabilities around the Disease Activity probability for each sample:

$$S_{pth} = \text{Clip}_{0}^{9} \left(\frac{1}{2} \text{Round} \left(18 \times \left(\frac{P_{pth} - P_{pth}^{Low}}{P_{pth}^{High} - P_{pth}^{Low}} + \frac{P_{DA} - P_{DA}^{Low}}{P_{DA}^{High} - P_{DA}^{Low}} - \frac{1}{N_{pth}} \sum_{pth'} \frac{P_{pth'} - P_{pth'}^{Low}}{P_{pth'}^{High} - P_{pth'}^{Low}} \right) \right) \right) + 1$$
(2)

"Clip" and "Round" served the same purpose in Eq. 2 as in Eq.1. P_{pth} was the probability for pathway model pth. P_{DA} was again the probability output by the final stage of the stacked classifier. The "High" and "Low" Ps for each pth served a similar purpose to those for the Disease Activity: rescaling the model probabilities so that they had a larger dynamic range. Lastly, N_{pth} was the number of pathway models that fed into the final layer of the stacked classifier model. In this case, N_{pth} =4.

The probabilities associated with each layer of the stacked classifier had a closed analytic form as well. Working backward from the final Disease Activity score, the Disease Activity probability had the form:

$$P_{DA} = \frac{1}{1 + e^{-\left(C_{DA}^{0} + \sum_{feat} C_{feat} V_{feat}\right)}}$$
(3)

 C^0_{DA} was the intercept (or bias) value for the Disease Activity meta-classifier. C_{feat} was the coefficient associated with V_{feat} . V_{feat} was the value of the feature being summed, either the probability for one of the pathways from the first layer of the model (written out explicitly in Eq. 4) or the age- and sex- corrected, log_{10} , LOQ-imputed concentrations that fed into the first-layer pathway models. These meta-

Qureshi et al Biomarker Analytical Validation Manuscript *Proteomics Clin Appl* classifier coefficients were fit using L2-penalized logistic regression with Gd+ lesion presence as the dependent variable, an intercept, and the stacked classifier features as the independent variables, with inverse regularization strength C=1.0, balanced class weight, and tolerance =0.0001, with the 'lbfgs' solver.

The individual pathway probabilities had the form:

$$P_{pth} = \frac{1}{1 + e^{-(C_{pth}^0 + \sum_{prot} C_{prot} V_{prot})}}$$
(4)

 C^0_{pth} was the intercept value for the pathway model in question. C_{prot} was the coefficient for a protein in pathway pth. V_{prot} was the demographically corrected, log_{10} , LOQ-imputed concentration of protein prot. These coefficients were fit using L2-penalized logistic regression with Gd+ lesion presence as the dependent variable, an intercept, and the pathway's demographically corrected (for age, sex), log_{10} , LOQ-imputed protein concentrations as the independent variables. The final pathway coefficients were the result of a stratified, 10-fold cross-validation with 3 repeats, grid-searched over inverse regularization strength C=[100, 10, 1.0, 0.1, 0.01], class weights=[None, balanced], solvers=["saga," "lbfgs," "liblinear"], and tolerances=[0.01, 0.001, 0.0001]. The demographic correction for the log_{10} of the LOQ-imputed protein concentration had the form:

$$V_{prot} = log_{10} \left(A_{prot} \left[\frac{pg}{mL} \right] \right) - \left[D_{prot,0} + \left(D_{prot,Sex} \times Sex \right) + \left(D_{prot,Age} \times Age[years] \right) \right]$$
(5)

 A_{prot} was the LOQ-imputed absolute concentration of protein prot in pg/mL (the units of these direct measurements have been written explicitly for added clarity). $D_{prot, 0}$, $D_{prot, Sex}$, and $D_{prot, Age}$ were the intercept, sex, and age coefficients for demographic correction, respectively. These coefficients were fit using the following procedure on three datasets not reported here. The dataset used to train the stacked classifier and pathway models provided the final non-zero coefficients for the

Qureshi et al Biomarker Analytical Validation Manuscript *Proteomics Clin Appl* demographic correction. The demographic correction coefficients were fit independently on each dataset using linear regression using StatsModels OLS[4] with log₁₀, LOQ-imputed protein concentration as the dependent variable, an intercept, and age and sex as the independent variables, after outliers were removed. Outliers were defined for each dataset as ≥96th percentile or ≤4th percentile for log₁₀, LOQ-imputed protein concentration. After fitting the linear regression, the age and sex coefficients were set to zero if the 95% confidence interval contained zero in any of the three datasets or if the sign of the coefficient was not consistent across three datasets. Sex was 0 for women and 1 for men, and age was the patient's age in years at time of blood draw.

Finally, see below for tables of the coefficients used in each step of the scoring process. First, we tabulated the demographic correction coefficients. These were the *D*s in Eq. 5.

Protein	Sex	Age	Intercept
APLP1	-0.052	0	4.065
CCL20	0	0	1.088
CD6	0	0	1.959
CDCP1	0	0.006	1.64
CNTN2	0	0.002	3.128
CXCL13	0	0	1.819
CXCL9	0	0.005	1.419
FLRT2	0	0	1.968
GFAP	-0.05	0.005	1.692
IL-12B	0	0	2.062
MOG	-0.04	0.003	1.267
NfL	0	0.008	0.5
OPG	-0.014	0.002	2.743

39

Qureshi et al Biomarker Analytical Validation Manuscript Proteomics Clin Appl

OPN	0.045	0	4.172
PRTG	0	0	2.052
SERPINA9	0	0	1.56
TNFRSF10A	0	0.003	0.565
TNFSF13B	0	0	3.75

Next, we tabulated the protein coefficients for each pathway. These were the Cs in Eq. 4.

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

Neuroinflammation:

Feature	Coefficient
CCL20	0.397
CD6	0.243
CXCL13	0.668
CXCL9	0.778
IL-12B	-1.515
TNFRSF10A	0.089
TNFSF13B	-2.705
Intercept	-0.283

• Immunomodulation:

Feature	Coefficient
CD6	0.825
CDCP1	-0.633
CXCL13	1.075
CXCL9	1.178
IL-12B	-1.657
TNFSF13B	-4.232
Intercept	-0.483

• Neuroaxonal Integrity:

Feature	Coefficient
APLP1	-0.149
CNTN2	-0.434
FLRT2	-0.321
GFAP	0.024
NfL	2.998
OPG	0.384

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

OPN	0.026
PRTG	-0.621
SERPINA9	-0.779
TNFRSF10A	-0.284
Intercept	-0.744

Myelin Biology:

Feature	Coefficient
APLP1	-1.206
MOG	2.653
OPN	-0.037
Intercept	-0.552

Then we tabulated the meta-classifier coefficients for the second stage of the stacked classifier. These were the *C*s in Eq. 3.

Feature	Coefficient
APLP1	-0.363
CCL20	0.222
CD6	0.119
CDCP1	-0.524
CNTN2	-0.21
CXCL13	0.1
CXCL9	0.252
FLRT2	-0.111
GFAP	0.042
IL-12B	-0.432
MOG	0.485
NfL	2.038
OPG	0.056
OPN	-0.072
PRTG	0.768
SERPINA9	0.142
TNFRSF10A	-0.178
TNFSF13B	-1.3
Neuroinflammation pathway	1.14

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

classifier	
Immunomodulation pathway classifier	1.737
Neuroaxonal integrity pathway classifier	1.525
Myelin biology pathway classifier	0.435
Intercept	-2.51

Finally, we tabulated the low and high values for scaling the probabilities in Eq.1 and Eq.2.

Disease Pathway/Disease Activity score	P _{Low pth}	P _{High pth}
Disease Pathway		
Immunomodulation	0.05	1.0
Myelin Biology	0.2	0.6
Neuroaxonal Integrity	0.1	1.0
Neuroinflammation	0.15	0.95
Disease Activity	0.05	1.00

Abbreviations: $P_{High\,pth}$, high values for scaling probabilities; $P_{Low\,pth}$, low values for scaling probabilities.

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

FILE S2. Assay interferents

Samples were analyzed for potential interference with endogenous substances found naturally in patients' samples (eg, lipemia, hemolysis, high protein count, and high bilirubin levels) and heterophilic antibodies such as HAMA and RF. Serum pools (*n*=4) were spiked with bilirubin, hemolysate, and lipids at typical concentrations using the ASSURANCE™ Interference Test Kit (Sun Diagnostics).

Heterophilic antibodies, including RF and HAMA, are established sources of potential interference in immunoassays. RF concentrate (Lee BioSolutions, Maryland Heights, MO, USA) was used to spike six serum samples at low (150 IU/mL) and high (2000 IU/mL) concentrations to determine the effect of RF interference on the analysis. For HAMA interference, five HAMA-positive serum samples with known established HAMA levels (ASSURANCE™ Interference Test Kit) were mixed at different ratios (10:90; 50:50; 90:10) with four MS samples from an internal cohort. Two HAMA-positive samples had a titer level >240 and three samples had a titer level >480, indicating that the positive samples had either >240 or >480 times more activity than a known negative. The mixed samples were compared with expected ratios of the individually measured samples to calculate the percent recovery.

Except for heterophilic antibody interference, the mean percentage recovery was calculated relative to the corresponding spike control (representing the same alteration of the serum sample without the addition of the interferent). For heterophilic antibody interference, the mean percentage recovery was calculated by comparing the RF spiked (low and high concentrations) samples with a corresponding spike control.

Qureshi et al Biomarker Analytical Validation Manuscript Proteomics Clin Appl

TABLE S1 Protein biomarkers included in assay panel to perform the MSDA Test

Biomarker	Full name	UniProt identifier
APLP1	Amyloid beta precursor-like protein 1	P51693
CCL20	C-C motif chemokine ligand 20 (MIP 3-alpha)	P78556
CD6	Cluster of differentiation 6	P30203
CDCP1	CUB domain-containing protein 1	Q9H5V8
CNTN2	Contactin 2	Q02246
CXCL13	Chemokine (C-X-C motif) ligand 13	P02462
CXCL9	Chemokine (C-X-C motif) ligand 9 (MIG)	O43927
COL4A1 ^a	Collagen type IV alpha 1	Q07325
FLRT2	Fibronectin leucine-rich repeat transmembrane protein	O43155
GFAP	Glial fibrillary acidic protein	P14136
<i>GH</i> ^a	Growth hormone (somatotropin)	P01241
IL-12β	Interleukin-12 subunit beta	P29460
MOG	Myelin oligodendrocyte glycoprotein	Q16653
NfL	Neurofilament light polypeptide chain	P07196
OPG	Osteoprotegerin	O00300
OPN	Osteopontin	P10451
PRTG	Protogenin	Q2VWP7
SERPINA9	Serpin family A member 9	Q86WD7
TNFRSF10A	Tumor necrosis factor receptor superfamily member 10A (TRAIL-R1)	O00220
TNFSF13B	Tumor necrosis factor superfamily member 13B (BAFF)	Q9Y275
VCAN ^a	Versican core protein	P13611

^aThese biomarkers were not used in the algorithm to determine Disease Pathway and Disease Activity scores.

Qureshi et al Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

TABLE S2 Common over-the-counter and prescription drugs, reference materials and standards, and mAbs evaluated for interference in the MSDA Test

Assay interferents	Concentration
Common drugs	
Acetaminophen	15.6 mg/dL
Ampicillin Na	7.5 mg/dL
Acetylsalicylic acid	3 mg/dL
Doxycycline HCI	1.8 mg/dL
Cefoxitin Na	660 mg/dL
Heparin	3300 U/L
Cyclosporine	0.18 mg/dL
Levodopa	0.75 mg/dL
Ibuprofen	21.9 mg/dL
Methyldopa	2.25 mg/dL
Phenylbutazone	32.1 mg/dL
Metronidazole	12.3 mg/dL
Rifampicin	4.8 mg/dL
Theophylline	6 mg/dL
Acetylcysteine	15 mg/dL
Reference materials and standards to evaluate DMTs	
Interferon β-1A (Avonex, Rebif)	0.56 ng/mL
Dimethyl fumarate (Tecfidera)	3.74 μg/mL
Fingolimod (Gilenya)	8.8 ng/mL
Teriflunomide (Aubagio)	90.6 μg/mL
Mitoxantrone (Novantrone)	0.674 μg/mL
Rituximab (Rituxan)	370 μg/mL
Methylprednisolone	0.141 μg/mL
Cladribine (Mavenclad)	0.058 μg/mL
Glatiramer acetate (Copaxone, Glatopa)	1.0 μg/mL
Vitamin D2 (Ergocalciferol)	0.2 μg/mL

Qureshi et al Biomarker Analytical Validation Manuscript Proteomics Clin Appl

Universal mAb surrogates^a

High concentration 424 μg/mL

Low concentration 7.93 µg/mL

^aSurrogates for natalizumab, ocrelizumab, alemtuzumab, and ofatumumab.

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

TABLE S3 Lot to lot (batch 1 vs. batch 2) and laboratory to laboratory (development vs. clinical laboratory) consistency of the MSDA Test

	Mean %	difference	R ² correlation	on of samples
	Batch 1 vs. batch 2	Development vs. clinical laboratory	Batch 1 vs. batch 2	Development vs. clinical laboratory
APLP1	0	-1	0.93	0.95
CCL20	-14	-12	0.99	1.00
CD6	-9	-9	0.97	0.97
CDCP1	-9	-10	0.99	1.00
CNTN2	8	4	0.96	0.97
COL4A1	-27	-17	0.97	0.98
CXCL13	-7	-5	0.99	1.00
CXCL9	-16	-11	1.00	1.00
FLRT2	-3	-6	0.95	0.98
GFAP	-13	-9	0.96	0.97
GH	-3	-6	0.98	0.99
IL-12β	-5	-5	0.97	0.98
MOG	2	0	0.98	0.98
NfL	-13	-10	0.98	0.99
OPG	-17	-9	0.97	0.98
OPN	-14	-7	0.97	0.99
PRTG	0	-5	0.97	0.98
SERPINA9	-4	-5	0.99	0.99
TNFRSF10 A	-7	-11	0.98	0.99
TNFSF13B	-6	-5	0.96	0.98

Qureshi et a	l Biomark	ker Analytical Vali	dation Manuscript	Proteomics	Clin Appl
VCAN	-8	-9	0.91	0.95	

Proteomics Clin Appl

TABLE S4 Storage, processing, and stability of the individual biomarkers at various temperatures (room temperature, 4°C, and

-20°C) over time during the initial and follow-up studies

	٠				Me	an % d	ifferer		-		ntal co	ntrol c	onditi	ons				ı			196
								Ir	nitial s	tudy								Fo	llow-ເ	up stu	ıdy 🖁
		Ro	om te	mper	ature				4	·°C					–20°C				4°	C	All 5
Analyte	4 h	Da y 1	Da y 3	Da y 7	Dа У 14	Day 28	4 h	Da y 1	Day 3	Day 7	Day 14	Day 28	Day 1	Day 3	Da y 7	Day 14	Dа У 28	Da y 1	Da y 2	Da y 3	Data Reserve
APLP1	4	17	7	19	48	134	-6	-8	12	31	12	25	5	9	0	5	10	10	5	7	11 ^ë 5
CCL20	4	2	-6	-7	8	47	1	-3	11	24	15	23	12	13	6	5	7	-1	-2	4	126 M
CD6	-2	-4	-14	-5	19	93	-10	-1 1	-7	7	-2	10	1	5	-1	1	1	2	-1	2	allowed
								-1										4	1	3	4 withou
CDCP1	-5	-1	-13	-2	26	114	-10	0	-2	6	1	10	0	7	-3	1	1				t perm
CNTN2	0	-3	-13	-3	24	71	-8	-1 0	-9	2	-3	7	2	6	1	2	3	3	0	1	1 license to
								-1										9	-3	11	14 gsplay
COL4A1	-5	-3	-14	-1	22	91	-10	1	-12	2	-2	10	0	4	9	3	2	0	0	0	1 Pe
					-2													2	0	0	1 76
CXCL13	-1	-7	-25	-27	4	7	-5	-6	-8	-6	-4	-3	6	12	4	7	5				1

						72		-1										5	2	4	7
VCAN	-3	-3	-10	-1	23	72	-6	1	-1	9	0	7	0	4	-2	2	1				

Proteomics Clin Appl

Green shading: %CV within ±20%. Red shading: %CV < −20% or >20%.

Biomarker Analytical Validation Manuscript

52

Qureshi et al

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

TABLE S5 Storage, processing, and stability of the MSDA Test during various

freeze-thaw cycles for individual biomarkers

		Free	eze-thaw c	ycle	
Analyte	Cycle 1	Cycle 2	Cycle 3	Cycle 4	Cycle 5
APLP1	-6	6	-13	-5	- 7
CCL20	-7	-2	-13	-10	-11
CD6	-1	0	-9	-8	-7
CDCP1	-1	-1	-11	-8	-7
CNTN2	1	3	-6	-1	-3
COL4A1	2	3	-11	-5	- 7
CXCL13	-1	-5	-11	-10	-9
CXCL9	-1	1	-11	-5	-7
FLRT2	-2	-3	-10	-10	-8
GFAP	-9	-4	-20	-23	-28
GH	-7	1	-12	-15	-13
IL-12β	-4	0	-13	-7	-9
MOG	-3	1	-11	-7	-9
NfL	1	-2	-12	-12	-1
OPG	-1	-3	-11	-6	-8
OPN	-3	-2	-11	-7	-9
PRTG	-3	-1	-10	-9	-8
SERPINA9	13	-2	-13	-11	-12
TNFRSF10 A	-8	2	-12	-8	-9
TNFSF13B	-1	0	-9	-4	-7
VCAN	-1	1	-8	-4	-6

Green shading: average % difference within ±20%. Red shading: average % difference < -20%.

e _{-80°}		7020		om tem				-80°				ŀ°C			n Appl est at va │ -80°c	l		-20 C			Sample			Freeze-			
C	4		Day	Day	Day	Day	Day	C	4 h		Day	Day	Day	Day	_ 000	Day	Day	Day	Day	Day	ID	Fresh	1	2	3	4	5
3	3		3	3	3	14 3	28 2.5	3	3.5	2.5	3	3.5	3.5	28	3	2.5	3	7 3.5	14 2.5	28 2.5	Е	5	5.5	5	5	4	5.5
4			4.5	4.5	4.5	4.5	3.5	4	4			4.5	5	5	4	4.5	4.5	4.5	5	5	F	6.5	7	6.5	7	6.5	7
7			6	7	7	6.5 9	6.5 8.5	7	7	7.5 8.5	7	7	7.5	7 9	7	6 8.5	6.5	7	6.5 8.5	7 8.5	G H	3 2.5	3.5	3 2.5	3.5 2.5	3.5 2.5	3.5

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

TABLE S7 Follow-up study of the storage, processing, and stability of the MSDA

Test at 4°C over time at the Disease Activity score level

Sample ID	−80° C		4°	C	
•	000	Day 1	Day 2	Day 3	Day 7
Α	8.5	8.5	8.5	8.5	8.5
В	5	4.5	4.5	4.5	4.5
С	7.5	6	7.5	7.5	7
D	6.5	6.5	6.5	5.5	7
E	5	5	5	5	5.5
F	7	7	7	6.5	7.5
G	5.5	5	5	5	5.5
Н	6.5	6.5	7.5	7.5	7.5
I	6	6	6.5	6	7
J	3.5	3.5	3	3.5	3
K	1.5	1	1.5	1.5	1.5
L	2.5	2.5	2.5	2.5	2
M	2.5	2.5	3	2	3
N	7.5	7.5	8.5	8	8

Low (1.0□4.0) Disease Activity scores are noted in green, moderate (4.5□7.0) Disease Activity scores are noted in blue, and

high (7.5□10.0) Disease Activity scores are noted in orange.

Qureshi et al Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

FIGURE S1. Overview of PEA technology and MSDA Test format. Eighteen antibody pairs, labeled with DNA oligonucleotides, bind to target antigen in solution.

Oligonucleotides that are brought into proximity will hybridize and are extended by a DNA polymerase. This newly created piece of DNA barcode is amplified by PCR. The amount of each DNA barcode is quantified by microfluidic qPCR (Biomark™ HD, Fluidigm, Maryland Heights, MO, USA), with results reported in cycle threshold values. Data processing is then performed in the Olink® NPX Manager (Olink Proteomics, Uppsala, Sweden) software to convert the Ct values to a Normalized Protein eXpression value. The signal obtained from the assay (Normalized Protein eXpression) is converted to absolute concentration (pg/mL) using three calibrators that cover the range of sample response in the MS population (calibrators: high, middle, low) and then referenced back to the standard curve. These concentrations are then used as inputs into algorithms corresponding to disease activity and biological pathway scores.

Octave Disease Activity Test Proteomic Analysis

target sequence.

This newly created DNA

reporter sequence is then

amplified by PCR

(Proximity Extension

Assay).

Octave uses a custom assay panel run on the Olink platform. EXTENSION Probe sequences in close proximity hybridize, forming a new PCR

Eighteen antibody pairs

labeled with probes are

allowed to pair-wise bind

to the target proteins

present in a serum

sample.


The amount of each DNA reporter sequence is detected by qPCR and the absolute concentrations (in pg/mL) of the target proteins are determined These concentrations are used as inputs into the disease pathway and disease activity score algorithms.

DETECTION

Biomarker Analytical Validation Manuscript

Proteomics Clin Appl


FIGURE S2. Assay interference using common drugs.



Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

FIGURE S3. Assay interference using routine endogenous interferents and heterophilic antibodies.



Qureshi et al Biomarker Analytical Validation Manuscript Proteomics Clin Appl

FIGURE S4. Percent difference of the observed protein concentration relative to the average concentration as determined from six time points (days 1, 2, 3, 4, 5, and 12) in eight samples assayed in the MSDA Test.



Qureshi et al Biomarker Analytical Validation Manuscript

Proteomics Clin Appl

REFERENCES

- [1] Raschka, S. (2018). MLxtend: providing machine learning and data science utilities and extensions to Python's scientific computing stack. *J Open Source Softw*, 3, 638.
- [2] Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., ... Duchesnay, E. (2011). Scikit-learn: Machine learning in Python. *Journal of Machine Learning Research*, *12*, 2825–2830.
- [3] Chitnis, T., Foley, J., Ionete, C., El Ayoubi, N., Saxena, S., Gaitan-Walsh, P., ... Khoury, S. J. Clinical validation study results of a multivariate proteomic serum based assay for disease activity assessments in multiple sclerosis. Presented at: 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 13-15, 2021; Virtual.
- [4] Seabold, S., Perktold, J. (2010). Statsmodels: Econometric and statistical modeling with Python. *Proceedings of the 9th Python in Science Conference*, 92–96.